Inclusion Criteria:

          -  Prior diagnosis of Stage 0 to III breast cancer that is estrogen receptor negative,
             progesterone receptor negative with completion of definitive surgery, radiation
             therapy and/or chemotherapy.

          -  Completion of chemotherapy or trastuzumab for > six months and of radiation therapy
             for > 2 months, as applicable and 5 years or less from completion of standard therapy.

          -  Greater than 1 year from pregnancy, lactation.

          -  Mammogram within the eight months prior to study enrollment that is not suspicious for
             breast cancer (ACR Class I-III).

        Exclusion Criteria:

          -  Other current malignancy or metastatic malignancy of any kind.

          -  Ongoing chemotherapy, radiation therapy, or other cancer-related treatment.

          -  Subjects on Coumadin or other anticoagulants.

          -  Subjects with breast implants.

          -  Subjects who have had radiation to both breasts or who have undergone bilateral
             mastectomies.

          -  Barriers to fine needle aspiration sampling of breast adipose tissue and/or
             parenchymal breast tissue, including breast implants, history of radiation to both
             breasts, bilateral mastectomies, and/or insufficient breast adipose/parenchymal tissue
             for adequate fine needle aspiration (FNA) sampling.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, hypertension, or psychiatric illness/social situation that would limit
             compliance with study requirements.

          -  Chronic use of omega 3 fatty acid concentrates or capsules within the 3 months prior
             to entry on the study or any other supplements that might interact with omega 3 fatty
             acid supplements.

          -  Pregnant or nursing women.

          -  Known sensitivity or allergy to fish.

          -  Subjects on a standing regimen of full dose aspirin (greater than 325 mg/day), NSAIDs
             (nonsteriodal anti inflammatory drug) or NSAID-containing products.